Recombinant Mouse VSIG2 Fc Chimera Protein, CF

RecombinantMouse VSIG2 Fc Chimera (Catalog # 9598‑VS) inhibits IL-17 secretion by human peripheralblood mononuclear cells (PBMC), in the presence of anti-CD3 antibody. The ED50for this effect is 0.75-4.5 μg/mL.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse VSIG2 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IL-17 secretion by human peripheral blood mononuclear cells (PBMC). The ED₅₀ for this effect is 0.75-4.5 μg/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse VSIG2 protein
  

  Mouse VSIG2 (Val25-Ala244) Accession # Q9Z109-1	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: Q9Z109-1
• N-terminal Sequence: Val25
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 50 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 58-66 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse VSIG2 Fc Chimera Protein, CF

• 2210413P10Rik
• Cortical thymocyte-like protein
• CTH
• CTHCTXLcortical thymocyte receptor (X. laevis CTX) like
• CT-like protein
• CTXL
• V-set and immunoglobulin domain containing 2
• V-set and immunoglobulin domain-containing protein 2
• VSIG2

Background

V-set and immunoglobulin domain-containing protein 2 (VSIG2), also known as CTM or CT-like protein, is a member of the much larger Ig superfamily. Mature mouse VSIG2 is a single-pass type I transmembrane protein with a 220 aa extracellular domain (ECD) and a 63 aa cytoplasmic region linked by a short transmembrane domain. The ECD of VSIG2 contains one Ig-like C2-type (immunoglobulin-like) and one Ig-like V-type (immunoglobulin-like) domain. Mouse VSIG2 ECD shares 85% and 94% identity with human and rat, respectively. In humans, VSIG2 is highly expressed in stomach, colon, prostate, trachea and thyroid glands and weakly in bladder and lung (1). V-set domains are Ig-like domains resembling the antibody variable domain and are found in diverse protein families from immunoglobulin light and heavy chains to T cell receptors and adhesion molecules (2). Several VSIG molecules, including VSIG1 and VSIG4, can be classified into the junctional adhesion molecule (JAM) family based on the immunoglobulin folds, V‐ and C2‐types, found in the ECD (3, 4). While the function of VSIG2 is currently unknown, based on the structural similarity to JAM molecules, it is most likely a cell adhesion molecule (2-4). R&D Systems in-house testing indicates that VSIG2 inhibits anti-CD3 antibody induced IL-17 secretion in human PBMC.

Bioinformatics

• Uniprot:
  • Q9Z109-1()